Literature DB >> 10080225

A clinical and molecular genetic analysis of solitary ocular angioma.

A R Webster1, E R Maher, A C Bird, Z J Gregor, A T Moore.   

Abstract

OBJECTIVES: To determine whether ocular angioma can occur in the absence of von Hippel Lindau (VHL) syndrome, to define the clinical characteristics of sporadic (non-VHL) angioma, and to estimate a prevalence for sporadic ocular angioma. DESIGN AND PARTICIPANTS: A cross-sectional study of a cohort of patients with apparent sporadic ocular angiomatosis recruited from throughout the United Kingdom. INTERVENTION: Clinical details and a family history were obtained for the patients in the cohort. Systematic ocular examination and further systemic screening were performed on the patients and relatives when possible. Leukocyte DNA was examined for VHL germline mutations. MAIN OUTCOME MEASURES: Patients with solitary and typical VHL-like ocular angioma, without clinical and family histories for VHL, were selected as possible sporadic (non-VHL) ocular angioma cases. An estimate of the population prevalence of sporadic (non-VHL) ocular angioma was made from patients presenting in the East Anglian region of the United Kingdom over a 25-year period.
RESULTS: From 32 patients referred, 17 had typical solitary ocular angioma and no evidence of other VHL complications in themselves or in family members. All 17 patients were negative for germline VHL mutations. The mean age of presentation was 30.9 years (median, 27.5; range, 3-52); 11 of 17 eyes suffered visual loss and 4 of 17 tumors occurred on the optic disc. The estimated prevalence of non-VHL ocular angioma was 9.0 x 10(-6), 95% confidence interval (CI) = 3.3 - 19 x 10(-6) (1 in 110,000 persons, 95% CI = 1 in 53,000-300,000).
CONCLUSIONS: Sporadic ocular angioma can occur in the absence of VHL disease but appears less prevalently than VHL itself. The age of presentation, degree of visual morbidity, complications, morphology, and anatomic location of tumors are similar to those seen in VHL disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080225     DOI: 10.1016/S0161-6420(99)90127-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma.

Authors:  Vincenzo Russo; Andrea Stella; Antonio Barone; Ingrid U Scott; Nicola Delle Noci
Journal:  Int Ophthalmol       Date:  2012-01-22       Impact factor: 2.031

Review 2.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Cerebellar hemangioblastoma in a patient with von hippel-lindau disease : a case report.

Authors:  D Abd Hamid; J Abdullah; A Ariff; M Muhamad; M Madhavan
Journal:  Malays J Med Sci       Date:  2000-07

Review 4.  Von Hippel-Lindau Disease and the Eye.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02

5.  Retinal angioma of Von hippel-lindau disease: A case report.

Authors:  O Nabih; H Hamdani; L El Maaloum; B Allali; A El Kettani
Journal:  Ann Med Surg (Lond)       Date:  2022-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.